Monoclonal antibody therapy-associated neurological disorders.
Several neurological disorders have been associated with the use of monoclonal antibodies (mAbs), especially those targeting tumor necrosis factor (TNF) and its receptors. These disorders include, among others, multiple sclerosis, optic neuritis, and various forms of peripheral demyelinating neuropathy. Progressive multifocal leukoencephalopathy, the natural course of which is lethal within months, has been mainly associated with the anti-α4-integrin mAb natalizumab and, to a lesser extent, with rituximab, alemtuzumab and efalizumab. The prevalence of demyelinating disease induced by biological therapies, as reported in randomized controlled trials and postmarketing studies, has been estimated to range from 0.02-0.20%. Peripheral neuropathies can occur early or late after initiation of therapy. Short-term follow-up indicates relatively good outcomes, sometimes after mAb discontinuation alone, although corticosteroids or intravenous immunoglobulin may be necessary to reverse and stabilize the condition. Definitive cessation of the biological therapy should be discussed on a case-by-case basis. Prospective postmarketing studies in which the control group includes patients with rheumatic autoimmune diseases-most notably rheumatoid arthritis-treated with conventional therapies could help us to evaluate the real risks and outcomes in patients receiving mAbs who develop neurological diseases.
Department of Internal Medicine, University of Barcelona, Villarroel 170, 08036-Barcelona, Spain. xavbosch@clinic.ub.es
Xavier
X
Bosch
Albert
A
Saiz
Manuel
M
Ramos-Casals
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000276:immunology / Q000517:prevention & control; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control; D011358:Product Surveillance, Postmarketing; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha
Brain. 2005 Apr;128(Pt 4):867-79
15705608
Best Pract Res Clin Rheumatol. 2008 Oct;22(5):847-61
19028367
J Rheumatol. 2004 Oct;31(10):2079-81
15468380
Neurology. 1999 Aug 11;53(3):457-65
10449104
Medicine (Baltimore). 2007 Jul;86(4):242-251
17632266
Muscle Nerve. 2008 Mar;37(3):281-92
18041052
Muscle Nerve. 2008 Oct;38(4):1318-25
18671292
Arch Neurol. 2006 Oct;63(10):1475-8
17030665
Neurology. 2005 Apr 26;64(8):1468-70
15851749
Muscle Nerve. 2010 May;41(5):723-7
20405504
J Rheumatol. 2003 Oct;30(10):2287-91
14528531
Arthritis Rheum. 2000 Feb;43(2):243-9
10693862
J Neurol Sci. 2006 May 15;244(1-2):133-6
16527311
Mol Biol Rep. 2011 Aug;38(6):4137-44
21136171
Arch Neurol. 2008 Sep;65(9):1162-5
18779418
Arthritis Rheum. 2006 May;54(5):1429-34
16645971
J Neurol Sci. 2010 Apr 15;291(1-2):103-6
20116808
Ann Rheum Dis. 2007 Jun;66(6):732-9
17329305
N Engl J Med. 2009 Sep 10;361(11):1075-80
19741228
Neurology. 2010 Jan 5;74 Suppl 1:S31-40
20038761
Clin Rheumatol. 2007 Feb;26(2):281-2
17063281
Clin Rheumatol. 2007 Feb;26(2):258-60
16683176
Pharmacol Ther. 2008 Feb;117(2):244-79
18155297
N Engl J Med. 2008 Oct 23;359(17):1786-801
18946064
Neurology. 2004 Nov 9;63(9):1754
15534279
N Engl J Med. 2009 Sep 10;361(11):1067-74
19741227
Inflamm Bowel Dis. 2009 Sep;15(9):1308-19
19434735
Curr Rheumatol Rep. 2008 Dec;10(6):442-8
19007533
N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2
16510760
Arch Neurol. 2009 Apr;66(4):490-7
19364934
J Neuroimmunol. 2011 Feb;231(1-2):73-7
20937530
Neurology. 1996 Dec;47(6):1531-4
8960740
Arthritis Rheum. 2002 Nov;46(11):3107-8; author reply 3108-9
12428265
Lancet. 1994 Jul 30;344(8918):298-301
7914262
Ann Rheum Dis. 2006 Jul;65(7):889-94
16439435
Ann Rheum Dis. 2010 Sep;69(9):1691-3
19628820
Neurology. 1999 Sep 11;53(4):751-7
10489036
Am J Pathol. 1999 May;154(5):1417-22
10329594
Autoimmun Rev. 2010 Jan;9(3):188-93
19854301
Eur J Clin Pharmacol. 2010 Feb;66(2):199-206
19838692
Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S134-40
15552527
N Engl J Med. 2009 Sep 10;361(11):1041-3
19741226
Ann Neurol. 2010 Sep;68(3):271-4
20818784